



## Indications for use

Prospera<sup>™</sup> is a donor-derived cell-free DNA (dd-cfDNA) test for surveillance of rejection in post-renal-transplant patients. In a **surveillance** situation, Prospera testing is recommended at regular intervals: **1**, **2**, **3**, **4**, **6**, **9**, and **12 months** after renal transplant or most recent rejection (see below) to establish an individual baseline for dd-cfDNA levels, and to detect subclinical rejection. It should then be repeated quarterly for the life of the transplant.

## Proposed draw schedule (surveillance)



Prospera testing should also be considered in **clinically indicated** situations. The decision to order Prospera should be made in accordance with physician-assessed risk of active renal allograft rejection, including when a biopsy is considered or performed to evaluate suspected transplant rejection. Results should be interpreted alongside patient history and other clinical factors.



If you would like to discuss your clinic's draw schedule and indications for use in more detail, please contact the Prospera clinical team at transplantclinical@natera.com.

201 Industrial Road, Suite 410 | San Carlos, CA 94070 | www.natera.com | 1.650.249.9090 | Fax 1.650.730.2272

This test was developed by Natera, Inc., a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the US Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. © 2020 Natera, Inc. All Rights Reserved. PRO\_OS\_IndicationsForUse\_20191015\_NAT-801995\_Rev2\_OUTPUT

